Navigation Links
AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
Date:10/1/2013

NORTH CHICAGO, Ill., Oct. 1, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that new data from its phase II hepatitis C clinical development program will be presented at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C., November 1-5, 2013. In total, eight abstracts will be presented, four of which include additional analyses from the phase IIb AVIATOR study. The data examine sustained virologic response (SVR) concordance, patient adherence to the regimen, patient reported outcomes and the impact of ribavirin dose reduction.  

The Liver Meeting will precede AbbVie's reporting of initial results from the pivotal phase III clinical trials of the safety and efficacy of AbbVie's investigational triple direct-acting antiviral (DAA) regimen for the treatment of hepatitis C. Reporting of those results is expected to begin later this year.

"At AbbVie, we are committed to researching new therapies that maximize sustained virologic response  with the hope of providing much needed new options for people with hepatitis C," said Barry Bernstein, M.D., vice president, infectious disease development, AbbVie. "We are very encouraged as we await top-line results from our phase III program, which we will share later this year."

Additionally, the oral presentation at AASLD will provide results from the PEARL-I study evaluating an interferon- and ribavirin-free, two-DAA investigational regimen in genotype 1b treatment-naïve patients and prior null responders. AbbVie is also investigating drug combinations for additional genotypes and next generations of DAAs as part of their ongoing commitment to the HCV community.

A brief summary of AbbVie's abstract titles is presented below.

About AbbVie's HC
'/>"/>

SOURCE AbbVie Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
2. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
3. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
4. AbbVie Declares Quarterly Dividend
5. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
6. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
7. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
8. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
9. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
10. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
11. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... privately held medical device company, announced today that it ... Corporation (Tokyo Stock Exchange TYO: 8001) to sell its ... in Japan . ViewRay,s technology, the ... MRI-guided radiation therapy system that images and treats cancer ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
(Date:1/22/2015)... , Jan. 22, 2015  Bio-Techne Corporation (NASDAQ: ... Ella, the first member of the new Simple Plex ... brand.  This launch represents the re-branding of the previously ... Simple Plex platform is a transformative immunoassay technology which ...
Breaking Medicine Technology:ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... NeuroSigma, a Los Angeles-based neuromodulation company, today ... revealed that external Trigeminal Nerve Stimulation (eTNS™) increased ... with depression and mood regulation.  eTNS™ was shown ... significant reductions in depression severity during the 8-week ...
... federal audit contractors in Medicare is restricting the ability ... equipment to patients.  The American Association for Homecare is ... prevention efforts are effective at stopping fraud without ... June fraud prevention summit conducted by the U.S. Department ...
Cached Medicine Technology:Potential Mechanism of Action Identified for the Treatment of Major Depression With Trigeminal Nerve Stimulation (TNS) - The USB Port to the Brain™ 2Potential Mechanism of Action Identified for the Treatment of Major Depression With Trigeminal Nerve Stimulation (TNS) - The USB Port to the Brain™ 3Potential Mechanism of Action Identified for the Treatment of Major Depression With Trigeminal Nerve Stimulation (TNS) - The USB Port to the Brain™ 4Medicare's Audit Process Hampers Access to At-Home Care 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Lower-Auto-Insurance.com has released a ... kit in a car for reducing the costs of an ... will also be able to get lower prices for their vehicle ... an important role in determining policy costs. Because of this, ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Feb. 25 Over 700,000 Americans visit emergency rooms ... pharmaceutical drugs (JAMA). Adding insult to injury, many ... The most common mainstream flu medicine (Tamiflu) is no ... After reviewing 47 clinical trials, the Public Library of ...
... friends and colleagues can nominate healthcare professionals demonstrating ... May 31, 2009 LOS ANGELES, Feb. 25 ... accept nominations for its annual Inspired Comfort Awards ... manufacturer of healthcare apparel has awarded more than ...
... a Survey of More Than 300 Dentists30,000+ Dentists Converge ... In preparation for the Chicago Dental Society,s 144th annual ... professionals to Chicago this February, society members were asked ... habits, and more. More than 300 of the society,s ...
... 25 Missouri Congressman Roy Blunt tonight issued the ... Congress:"President Obama,s first address was a historic milestone for ... more with his assessment that while our country is ... great successes. On the issue of health care, ...
... Fla., Feb. 25 The Quantum Group, Inc. (NYSE ... Healthcare Services Organization (HSO), announced today that Senior Vice ... is scheduled to present at the 5th Annual Winter ... presentation is scheduled for 10:30 AM (pacific standard time) ...
... Donation Goal for Huntsman Cancer InstitutePARK CITY, Utah, Feb. 25 ... Diamond property, is designating Easter week - from April 6-12, ... five percent of all room revenue ... to Heal" campaign as a portion of the Lodge,s short-range ...
Cached Medicine News:Health News:No-Side-Effect Drugs Meet Today's Health Challenges 2Health News:Cherokee Inspired Comfort Awards Program Call for Nominations 2Health News:Cherokee Inspired Comfort Awards Program Call for Nominations 3Health News:Hard Economic Times Affect Patients, Dentists - and the Tooth Fairy 2Health News:The Quantum Group to Present at 5th Annual Winter Technology Conference 2Health News:The Quantum Group to Present at 5th Annual Winter Technology Conference 3Health News:The Quantum Group to Present at 5th Annual Winter Technology Conference 4Health News:Stein Eriksen Lodge Designates April 6-12 as 'Giving Room Week' 2
... Topcon, leader in the ... the most advanced technology ... conveniences and totally reliable ... Refractometry and Auto Kerato-Refractometry. ...
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
Designed for everyone working on clinical services, providing a streamlined, well-organized source of clinically relevant medical information....
... flowmeter with a Lexan®inner calibrated flow tube ... manufacturing defects. A wide range of configurations ... available with all popular inlet connections, a ... unit configurations. Our extra large knob coupled ...
Medicine Products: